AU2016355103B2 - Pyrropyrimidine compounds as MNKs inhibitors - Google Patents

Pyrropyrimidine compounds as MNKs inhibitors Download PDF

Info

Publication number
AU2016355103B2
AU2016355103B2 AU2016355103A AU2016355103A AU2016355103B2 AU 2016355103 B2 AU2016355103 B2 AU 2016355103B2 AU 2016355103 A AU2016355103 A AU 2016355103A AU 2016355103 A AU2016355103 A AU 2016355103A AU 2016355103 B2 AU2016355103 B2 AU 2016355103B2
Authority
AU
Australia
Prior art keywords
alkyl
compound according
compound
pyrrolo
tumours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016355103A
Other languages
English (en)
Other versions
AU2016355103A1 (en
Inventor
Stephen Lewis
Edward Giles Mciver
Joanne OSBORNE
Jon James Winter-Holt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
LifeArc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LifeArc filed Critical LifeArc
Publication of AU2016355103A1 publication Critical patent/AU2016355103A1/en
Application granted granted Critical
Publication of AU2016355103B2 publication Critical patent/AU2016355103B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2016355103A 2015-11-20 2016-11-16 Pyrropyrimidine compounds as MNKs inhibitors Ceased AU2016355103B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1520499.3 2015-11-20
GBGB1520499.3A GB201520499D0 (en) 2015-11-20 2015-11-20 Compounds
PCT/GB2016/053579 WO2017085483A1 (en) 2015-11-20 2016-11-16 Pyrropyrimidine compounds as mnks inhibitors

Publications (2)

Publication Number Publication Date
AU2016355103A1 AU2016355103A1 (en) 2018-05-31
AU2016355103B2 true AU2016355103B2 (en) 2021-07-08

Family

ID=55133105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016355103A Ceased AU2016355103B2 (en) 2015-11-20 2016-11-16 Pyrropyrimidine compounds as MNKs inhibitors

Country Status (9)

Country Link
US (1) US10604524B2 (enExample)
EP (2) EP3377494B1 (enExample)
JP (1) JP6946290B2 (enExample)
CN (1) CN108368114B (enExample)
AU (1) AU2016355103B2 (enExample)
CA (1) CA3003554C (enExample)
ES (2) ES2972862T3 (enExample)
GB (1) GB201520499D0 (enExample)
WO (1) WO2017085483A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
ES2969988T3 (es) 2017-02-14 2024-05-23 Effector Therapeutics Inc Inhibidores de Mnk sustituidos con piperidina y métodos relacionados con los mismos
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
WO2020086713A1 (en) 2018-10-24 2020-04-30 Effector Therapeutics, Inc. Crystalline forms of mnk inhibitors
CN110903286B (zh) * 2019-12-16 2021-09-24 沈阳药科大学 4,6-双取代吡啶[3,2-d]嘧啶类化合物及其制备和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040142A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
WO1998023613A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
US20100216788A1 (en) * 2005-12-02 2010-08-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN104744446A (zh) * 2013-12-30 2015-07-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
JP2004509059A (ja) 1999-06-03 2004-03-25 アボット・ラボラトリーズ 細胞接着抑制性抗炎症化合物
US20050165029A1 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
US8633201B2 (en) * 2006-04-07 2014-01-21 Boehringer Ingelheim International Gmbh Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2219649A2 (en) * 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
JP5626748B2 (ja) * 2008-07-02 2014-11-19 キッコーマン株式会社 ペプチド含有調味料
JP5575274B2 (ja) * 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
EP2539343B1 (en) 2010-02-26 2015-12-30 Evotec International GmbH Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
ES2653419T3 (es) 2013-02-01 2018-02-07 Bayer Pharma Aktiengesellschaft Pirazolopirimidinilamino-indazoles sustituidos
US9675612B2 (en) 2013-03-06 2017-06-13 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040142A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
WO1998023613A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
US20100216788A1 (en) * 2005-12-02 2010-08-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN104744446A (zh) * 2013-12-30 2015-07-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Also Published As

Publication number Publication date
JP2018534316A (ja) 2018-11-22
JP6946290B2 (ja) 2021-10-06
EP3792264A1 (en) 2021-03-17
EP3792264B1 (en) 2024-01-03
CA3003554A1 (en) 2017-05-26
CN108368114B (zh) 2023-10-24
EP3377494A1 (en) 2018-09-26
CA3003554C (en) 2023-08-29
AU2016355103A1 (en) 2018-05-31
HK1253576A1 (en) 2019-06-21
WO2017085483A1 (en) 2017-05-26
ES2972862T3 (es) 2024-06-17
EP3377494B1 (en) 2021-03-03
US10604524B2 (en) 2020-03-31
GB201520499D0 (en) 2016-01-06
CN108368114A (zh) 2018-08-03
US20180346469A1 (en) 2018-12-06
ES2872775T3 (es) 2021-11-02

Similar Documents

Publication Publication Date Title
EP2403853B1 (en) Pyrrolopyrimidines used as kinase inhibitors
US9879010B2 (en) Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors
US11136338B2 (en) Fused thiazolopyrimidine derivatives as MNKs inhibitors
AU2016355103B2 (en) Pyrropyrimidine compounds as MNKs inhibitors
HK40037886B (en) Pyrropyrimidine compounds as mnks inhibitors
HK40037886A (en) Pyrropyrimidine compounds as mnks inhibitors
HK40065647B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
HK40065647A (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
HK1253576B (en) Pyrropyrimidine compounds as mnks inhibitors
HK1253575B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
Webb-Smith 2) Patent Application Publication o Pub. No.: US 2020/0247822 A1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired